Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer Ingelheim

Showing 15 posts of 111 posts found.

bi_microparts_image

Boehringer injects €230 million in new Biologicals Development Center

June 26, 2018
Manufacturing and Production Boehringer Ingelheim, biologics, manufacturing, pharma

Prominent industry player Boehringer Ingelheim has unveiled plans to invest €230 million into the construction of a new Biologicals Development …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 6, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Boehringer Ingelheim, Kite, Nordic Nanovector, Pfizer, Roche, Sanofi, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

Some of the biggest news this week concerns companies that are looking to move on parts of their business, but …

News
bi_microparts_image

Boehringer terminates Alzheimer’s candidate after Phase 2 failure

February 12, 2018
Research and Development, Sales and Marketing Alzheimer's, Boehringer Ingelheim, dementia, pharma

Boehringer Ingelheim has announced its intention to halt development of its candidate BI 409306 in the treatment of Alzheimer’s after …

News

Boehringer’s Gilotrif approved in US for lung cancer with non-resistant EGFRs

January 16, 2018
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Cancer, FDA, Giltrif, NSCLC, lung cancer

Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include …

News

Boehringer scoops schizophrenia candidates for €627.5m

December 19, 2017
Manufacturing and Production, Sales and Marketing Autifony, Boehringer Ingelheim, biotech, drugs, pharma, pharmaceutical

Boehringer Ingelheim has moved early to secure an exclusive option on Autifony’s lead candidate for the treatment of schizophrenia, AUT00206, …

News
boehringer_biberach_germany_copy

Boehringer loses CFO over financial strategy dispute

December 18, 2017
Medical Communications, Sales and Marketing Boehringer, Boehringer Ingelheim, appointment, pharma

Boehringer Ingelheim is set to part ways with its Chief Financial Officer Simone Menne after 16 months due to fundamental …

News

Boehringer offers its molecules to the scientific community via new platform

November 21, 2017
Manufacturing and Production, Research and Development Boehringer Ingelheim, pharma

Boehringer Ingelheim has unveiled opnME.com, a centralised platform which makes available selected pre-clinical molecules from its portfolio for free, accessible …

News
bi_german_building_at_night

Boehringer celebrates EU approval of Humira biosimilar

November 14, 2017
Manufacturing and Production, Sales and Marketing Boehringer, Boehringer Ingelheim, Cyltezo, EU, Europe, European Commission, Humira, biosimilar

Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, …

News
boehringer_groundbreaking

Boehringer Ingelheim break ground on $217 million Fremont facility

August 1, 2017
Manufacturing and Production Boehringer Ingelheim, biotech, drugs, pharma, pharmaceutical

Boehringer Ingelheim announced that it had broken ground on its planned $217 million upgrade and expansion of its existing Fermont …

News
laurie-glimcher-large

GSK unveil appointment coup for board of directors

July 21, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, GSK, biotech, drugs, immunooncology, pharma, pharmaceutical

GSK continue its appointment spree with a particularly notable staff acquisition, with leading immuno-oncology scientist, Dr Laurie Glimcher, joining its …

Appointment
ipsen_small

Ipsen to acquire Sanofi assets in $88 million deal

February 13, 2017
Sales and Marketing Boehringer Ingelheim, Prontalgine, Sanofi, ipsen

Ipsen has announced that it is set to enter into a definitive agreement to acquire five consumer healthcare products from …

News
bi_german_building_at_night

Boehringer steps into Humira race with US and EU biosimilar filings

January 19, 2017
Sales and Marketing Boehringer Ingelheim, Humira, biosimilar

Boehringer Ingelheim has just stepped into the ring to battle it out for a slice of Humira’s revenue with accepted …

News
handshake

Sanofi and Boehringer confirm successful exchange of businesses

January 3, 2017
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Sanofi

Sanofi and Boehringer Ingelheim have confirmed the successful completion of the exchange of Sanofi’s animal health business (Merial, based in …

News
shutterstock_92671375

Five major pharma firms break ABPI code of conduct, according to watchdog

December 15, 2016
Medical Communications, Sales and Marketing ABPI, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Grunenthal, Janssen

Eli Lilly, Boehgringer Ingelheim, AstraZeneca UK, Grunenthal and Janssen-Cilag have been “named and shamed” by the Prescription Medicines Code of …

News

FDA approves another indication for Lilly/Boehringer diabetes treatment

December 5, 2016
Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance

Jardiance (empagliflozin), an oral SGLT02 inhibitor developed by Eli Lilly and distributed by Boehringer Ingelheim, has been approved by the …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024